11th week of 2010 patent applcation highlights part 51 |
Patent application number | Title | Published |
20100069411 | CANCER TREATMENT METHOD - The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound. | 2010-03-18 |
20100069412 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE - Quinazoline derivatives of formula (I): | 2010-03-18 |
20100069413 | Pyrimidine and Quinazoline Derivatives - This invention is concerned with compounds of the formula | 2010-03-18 |
20100069414 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM - The present invention relates to bicyclic heterocycles of general formula | 2010-03-18 |
20100069415 | 2,6-DIPHENYL-4,8-DIAZOADAMANTAN-1-ONE AND DERIVATIVES THEREOF, PROCESS OF MANUFACTURE AND USE FOR THE FORMULATION OF SOLUTIONS WITH STERILIZING AND DISINFECTANT EFFECT - A chemical compound having the following structural formula wherein optionally at least one of the phenyl —C | 2010-03-18 |
20100069416 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors - The present invention relates to certain azabicyclo compounds of formula (I)′: | 2010-03-18 |
20100069417 | NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS - The disclosure relates to a compound of formula (I): | 2010-03-18 |
20100069418 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS - The invention relates to piperidine compounds of formula (I) wherein X-R | 2010-03-18 |
20100069419 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention is directed to spiropiperidine compounds of formula (I) | 2010-03-18 |
20100069420 | SPIRO-PIPERIDINE INHIBITORS - Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein. | 2010-03-18 |
20100069421 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RADIATION PROCTOSIGMOITIS - The present invention provides a new method of preventing, ameliorating and/or treating enteritis induced by abdominopelvic therapies. The present invention also relates to the prophylactic treatment of traveler's diarrhea. | 2010-03-18 |
20100069422 | METHODS AND COMPOSITIONS FOR PROMOTING BONE AND JOINT HEALTH - Methods and compositions that can be used to promote bone and joint health through amelioration, stabilization and repair of damage associated with various pathophysiological conditions are disclosed. | 2010-03-18 |
20100069423 | Use of Chk2 Kinase Inhibitors for Cancer Treatment - Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof. | 2010-03-18 |
20100069424 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY - The present invention concerns the compounds of formula | 2010-03-18 |
20100069425 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE - The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof. | 2010-03-18 |
20100069426 | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer. | 2010-03-18 |
20100069427 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods - Imidazo[4,5-c] ring compounds, (e.g. imidazo[4,5-c]pyridines, imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridine, and 6,7,8,9-tetrahydro imidazo[4,5-c]naphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 2010-03-18 |
20100069428 | ACRIDONE COMPOUNDS - A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia. | 2010-03-18 |
20100069429 | Tea Polyphenol Composition and Method for Producing the Same - The objective of the present invention is to provide a tea polyphenol composition that has reduced bitterness and astringency while containing catechins with high purity. The present invention provides a tea polyphenol composition, (A) comprising 85% by weight to 95% by weight of catechins, (B) wherein the catechins contains epigallocatechin gallate and gallocatechin gallate at a ratio of 65% by weight to 80% by weight and (C) wherein the ratio given by (epigallocatechin gallate+gallocatechin gallate)/(epicatechin+catechin+epigallocatechin+gallocatechin+epicatechin gallate+catechin gallate) is from 2 to 4. | 2010-03-18 |
20100069430 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides novel pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump inhibitory effect. | 2010-03-18 |
20100069431 | IMIDAZOPYRIDINE COMPOUNDS - Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein. | 2010-03-18 |
20100069432 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors - Provided are bis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 2010-03-18 |
20100069433 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR HYPERLIPIDEMIA - The present invention provides a therapeutic agent for hyperlipidemia having an excellent effect of lowering the cholesterol and triglyceride level in blood plasma. | 2010-03-18 |
20100069434 | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein. | 2010-03-18 |
20100069435 | METHOD OF SELECTIVELY INTRODUCING AMINO SUBSTITUENT - Provided are a technique for position-selectively introducing an amino group into a difluorobenzoic acid, a novel process for producing a quinolonecarboxylic acid derivative serving as an antibacterial agent, and intermediates in the production. The process comprises treating a compound represented by formula (6): | 2010-03-18 |
20100069436 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT - The invention relates to imidazole derivatives of the Formula (I) in which the radicals R | 2010-03-18 |
20100069437 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - 4-Tetrazolyl-4-phenylpiperidine Compounds, compositions comprising an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound, methods for treating or preventing pain or diarrhea in an animal comprising administering to an animal in need thereof an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound and methods for stimulating opioid-receptor function in a cell comprising contacting a cell capable of expressing an opioid receptor with an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound are disclosed. | 2010-03-18 |
20100069438 | ANESTHESIA INDUCTION AND MAINTENANCE DRUG - Disclosed herein is a combination drug designed for use by anesthesiologists for the purposes of inducing and/or maintaining general anesthesia and minimizing the stress response to pain that results from the noxious stimuli associated with surgical procedures. The present invention is suitable for use in general anesthesia to decrease the need for muscle relaxant administering and permit patients to drive themselves home after receiving the anesthetic. This invention includes a combination drug comprised of propofol (2,6-diisopropylphenol) and remifentanil (N-phenyl-N-(4-piperidinyl)amides) in which the preferred embodiment contains 2 mcg of remifentanil for each 1 mg of propofol. The combination drug invention may include a package as two drugs of proper proportions shipped and sold in a two compartment vial or syringe for mixing immediately prior to use. Alternatively, the invention may comprise a single drug prepared with proper preservatives in an aqueous solution. | 2010-03-18 |
20100069439 | MICROORGANISM CONTROL AGENT AND STABILIZING METHOD - Disclosed is a microorganism control agent containing not less than 1% by weight but less than 10% by weight of N,N′-hexamethylenebis(4-carbamoyl-1-decylpyridinium bromide), not less than 35% by weight but less than 60% by weight of at least one alcohol having 2 or 3 carbon atoms, water and an acid. | 2010-03-18 |
20100069440 | PYRIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE - Disclosed are compounds of the formula I: | 2010-03-18 |
20100069441 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS - The present invention provides indoline heterocyclic compounds of the following formula I: | 2010-03-18 |
20100069442 | PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. | 2010-03-18 |
20100069443 | COMPOUND WITH BENZAMIDE SKELETON HAVING CYCLOOXYGENASE-1 (COX-1)-SELECTIVE INHIBITORY ACTIVITY - This invention provides a novel COX-1-selective inhibitor. This invention relates to a novel compound represented by the formula below or a salt thereof. This invention also relates to an analgesic agent, an antiinflammatory agent, an antitumor agent, an antiplatelet aggregation agent, and a cyclooxygenase-1-selective inhibitor comprising, as an active ingredient, such compound or salt thereof. | 2010-03-18 |
20100069444 | PHENATHRENONE COMPOUNDS, COMPOSITONS AND METHODS - The present invention is directed to compounds of Formula I: | 2010-03-18 |
20100069445 | METHOD FOR THE SEPARATION OF S-(-)-AMLODIPINE FROM RACEMIC AMLODIPINE - Disclosed is a method for the separation of S-(−)-amlodipine from a racemic amlodipine. Featuring the use of inexpensive L-tartaric acid as an optical resolution agent and DMAC as a solvent, the separation method allows the resolution of S-(−)-amlodipine from racemic amlodipine at high yield and to a satisfactory enantiomeric excess and thus is economically favorable and applicable to the mass production of the optical isomer. | 2010-03-18 |
20100069446 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX - The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same. | 2010-03-18 |
20100069447 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO - Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: | 2010-03-18 |
20100069448 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE - The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis. | 2010-03-18 |
20100069449 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT - Novel oxazolidinone derivatives with a difluorophenyl moiety, represented by Chemical Formula 1, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same as an active ingredient are provided. Exhibiting potent inhibitory activity against Gram-positive bacteria including | 2010-03-18 |
20100069450 | SALT OF 3-BENZYL-2-METHYL-2,3,3A,4,5,6,7, 7A- OCTAHYDROBENZO[D]ISOXAZOL-4-ONE - The present invention relates to fumarate salt of the compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive conditions, in the improvement of learning ability, in the reversal of amnesia, in resolving the abstinence syndrome from drugs and drugs of abuse. Preferably, the invention concerns fumarate salt of rel-(3R,3aS,7aS)-3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one. | 2010-03-18 |
20100069451 | SALT OF 3-BENZYL-2-METHYL-2,3,3A,4,5,6,7, 7A- OCTAHYDROBENZO[D]ISOXAZOL-4-ONE - The present invention relates to oxalate salt of the compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive conditions, in the improvement of learning ability, in the reversal of amnesia, in resolving the abstinence syndrome from drugs and drugs of abuse. Preferably, the invention concerns oxalate salt of rel-(3R,3aS,7aS)-3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one. | 2010-03-18 |
20100069452 | MINERALOCORTICOID RECEPTOR MODULATORS - The present invention relates to diphenylmethyl imidazole mineralocorticoid receptor modulators compounds having the structure | 2010-03-18 |
20100069453 | Certain Chemical Entities, Compositions, and Methods - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 2010-03-18 |
20100069454 | Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection - The present invention provides compounds, pharmaceutical compositions and methods for treating, immuno-allergical diseases, autoimmune diseases, and organ or tissue rejection following transplantation. | 2010-03-18 |
20100069455 | BONE MODEL, BONE FILLER AND PROCESS FOR PRODUCING BONE FILLER - A method for producing a bone filler basically comprising: a bone model producing step (step 1) for producing a bone model; a figure forming material filling step (step 2) for filling a figure forming material into a bone defect site of the bone model obtained in the bone model producing step; and a bone filler producing step (step 3) for producing a bone filler which is to be filled in a bone defect site based on the figure forming material filled in the bone defect site of the bone model in the figure forming material filling step. | 2010-03-18 |
20100069456 | USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS - Use of a compound of formula (I) in which R, R′ and R″ have the meanings given in the description, optionally in the form of a salt thereof with a pharmaceutically acceptable organic or mineral base, to prepare a pharmaceutical composition for reducing the blood triglyceride, cholesterol and glucose levels. | 2010-03-18 |
20100069457 | Naphthalene Derivatives Used As EP4 Receptor Agonists - A compound of formula (I) or a pharmaceutically acceptable derivative thereof, | 2010-03-18 |
20100069458 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER - The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination. | 2010-03-18 |
20100069459 | NOVEL FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-P- HENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID MAGNESIUM - Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described. | 2010-03-18 |
20100069460 | 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE - A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: | 2010-03-18 |
20100069461 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V LEIDEN MUTANT GENE - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell. | 2010-03-18 |
20100069462 | MITOCHONDRIAL FUNCTION OF PROHIBITIN 2 (PHB2) - The present invention relates to a PHB2 gene regulator and a therapeutic drug for mitochondrial-function-related disease containing the same, for example. | 2010-03-18 |
20100069463 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF AFFECTIVE DISORDERS AND CUSHING'S SYNDROMES - The present invention relates to a method for identifying a TMEFF2 modulator, comprising (a) contacting a cell which expresses TMEFF2 with a candidate compound to be tested; (b) measuring whether said compound to be tested decreases or increases the level of a constituent of the cAMP signalling pathway, preferably the CRH signalling pathway, in said cell when compared to a corresponding cell which does not express TMEFF2; (b′) optionally determining whether said compound is capable of reduncing the binding between Activin and TMEFF2; and (c) identifying said modulator compound. Furthermore, a method for identifying a TMEFF2 modulator comprising determining whether said TMEFF2 modulator is capable of reducing the binding between Activin and TMEFF2 is contemplated. It also relates to uses and methods applying a TMEFF2 agonist for the treatment of Cushing's Syndromes and a TMEFF2 modulator for the treatment of affective disorders. Furthermore, methods of diagnosing affective disorders or Cushing's Syndromes are provided. | 2010-03-18 |
20100069464 | COMPOSITIONS AND METHODS FOR MODULATING ACTIVITY OF CAPPED SMALL RNAS - Compositions and methods for modulating transcription by RNA polymerases are described. | 2010-03-18 |
20100069465 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery. | 2010-03-18 |
20100069466 | Compositions and Methods for the Systemic Treatment of Arthritis - The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β. | 2010-03-18 |
20100069467 | DOUBLE-STRANDED/SELF-COMPLEMENTARY VECTORS WITH A TRUNCATED CBA PROMOTER AND METHODS OF GENE DELIVERY - The present inventors concerns vectors carrying a truncated chimeric CMV-chicken β-actin (smCBA) promoter in which the hybrid chicken β-actin/rabbit β-globin intron is greatly shortened, and their use to deliver to an operatively linked polynucleotide to host cells in vitro or in vivo, resulting in expression of the polynucleotide in the host cells. In one embodiment, the vector carrying the smCBA promoter is administered to the eye. In another embodiment, the vector carrying the smCBA promoter is a self-complementary adeno-associated virus (AAV). The AAV vector may be of any serotype (e.g., type 1, type 2, type 3, type 4, type 5, type 6, type 7, type 8, type 9, type 10). In another embodiment, a self-complementary vector carrying the smCBA promoter is administered to the eye. Another aspect of the invention concerns host cells carrying a vector of the invention. Another aspect of the invention concerns pharmaceutical composition comprising the vectors or host cells of the invention, and a pharmaceutically acceptable carrier. | 2010-03-18 |
20100069468 | INHIBITION OF BETA-AMYLOID PEPTIDE AGGREGATION - The present invention relates to methods of using cocaine-binding-site ligands and cocaine-binding-site RNA aptamers to treat or prevent Alzheimer's Disease and to reduce or prevent aggregation of beta-amyloid peptides in a subject. | 2010-03-18 |
20100069469 | FORMULATIONS AND COMPOSITES WITH REACTIVE FILLERS - The invention provides composite materials prepared by i) providing a fluid formulation comprising (1) at least one compound capable of polymerisation and/or cross-linking and (2) a water-consuming reactive filler; ii) optionally injecting said formulation into a site of use; iii) polymerising and/or cross-linking said compound, to form a solid polymer matrix (which may be degradable or non-degradable); iv) causing or allowing said filler to react with water absorbed by said polymer matrix, to produce a solid filler material which is dispersed throughout the composite material. The hydration and formation of the solid filler in situ provides desirable properties to the composites, which have utility for dental composites, bone fillers and adhesives and so on. The composite may also be used to release an active ingredient e.g. an antibacterial or DNA. | 2010-03-18 |
20100069470 | IDENTIFICATION OF PROTEIN BIOMARKERS ASSOCIATED WITH LYMPH NODE METASTASIS IN COLORECTAL CANCER - Disclosed herein are compositions and methods relating to the diagnosis, prognosis, and treatment of colorectal cancer. The compositions and methods generally relate to the differential expression of transgelin in colorectal cancer cells with metastatic potential. | 2010-03-18 |
20100069471 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES - This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression. | 2010-03-18 |
20100069472 | COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN - Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. | 2010-03-18 |
20100069473 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase - Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: | 2010-03-18 |
20100069474 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS - The present invention is directed to novel coumarin derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels | 2010-03-18 |
20100069475 | METHOD OF ACTIVATING NK CELLS - The present invention provides a method of mediating hypo-activation of NK cells. Methods of the present invention comprise administering to a subject an effective amount of broad acting phosphotase inhibitor, such as sodium orthovanadate, SHP specific inhibitor. In one embodiment, the SHP specific inhibitor is NSC119910. | 2010-03-18 |
20100069476 | COMPOSITIONS AND METHODS FOR REDUCTION OF CUTANEOUS PHOTOAGEING - Compositions and methods are provided in which a topical hydrophilic formulation includes a catechin and a hydrophilic antioxidant in a hydrophilic composition at a ratio of between 2.3 to 1.7 (by weight), ad wherein the catechin and the antioxidant are present in an amount such that application of the composition to skin will deposit the catechin at a dosage of between 0.7 mg/cm2 and 1.3 mg/cm2. Especially preferred catechins include green tea catechins, and particularly EGCG, while preferred antioxidants include ascorbic acid and derivatives thereof. | 2010-03-18 |
20100069477 | METHIONINASE INHIBITOR AND COMPOSITION AND FOOD OR DRINK CONTAINING THE SAME - The invention provides a methioninase inhibitor to suppress the production of methyl mercaptan that is a causative substance of a bad smell by inhibiting methioninase originated from bacteria, as well as a composition and a food or drink containing the same, wherein the methioninase inhibitor contains an extract obtained from a plant of the family | 2010-03-18 |
20100069478 | ISOFLAVONE DERIVATIVES AND USES THEREOF - Isoflavone derivatives are provided comprising a carboxyalkylene moiety linked via its alkylene chain to the aromatic ring and via its carboxy group to an aminoalkyleneamino residue, which, in turn, is covalently linked to a functional group B. The isoflavone derivatives are preferably derived from biochanin A, genistein, and daidzein, and the functional group B is preferably an amino protecting group. These isoflavone derivatives are useful for treating or preventing diseases or disorders associated with estrogen receptor functioning. | 2010-03-18 |
20100069479 | NEURODEGENERATIVE DISEASE TREATMENT USING JAK/STAT INHIBITION - The invention relates to treatment of neurodegenerative diseases with JAK/STAT pathway inhibitors to eliminate extracellular cell signaling events leading to cell cycle abrogation and/or apoptosis. Primary neurons were administered neurotoxic proteins, such as gp120, Tat, or gp120 and Tat, with or without IFN-γ added, resulting in neuronal death, and simulated neurodegenerative diseases. The neurodegenerative disease is treated using a JAK/STAT pathway inhibitor, including (—)-epigallocatechin-3-gallate (EGCG), to modulate JAK1 or STAT1 phosphorylation, resulting in resistance to gp120 or Tat neurotoxicity. The invention may be used to treat neurons afflicted with HIV-associated Dementia, multiple sclerosis, Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, or Pick's Disease, and may act in conjunction with antiviral treatment, like HAART. | 2010-03-18 |
20100069480 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Isolated compounds and combinations of isolated compounds isolated from | 2010-03-18 |
20100069481 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Isolated compounds and combinations of isolated compounds isolated from | 2010-03-18 |
20100069482 | GEL USEFUL FOR THE DELIVERY OF OPHTHALMIC DRUGS - It is described a gel composed of a mixture of a polymer which forms a gel, a buffer; a saccharide and one or more active ingredients useful for treating diseases of the eyes. | 2010-03-18 |
20100069483 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE - Compounds of Formula I potently inhibit both cyclooxygenase-2 and carbonic anhydrases. Inhibition of carbonic anhydrases by a cyclooxygenase-2 inhibitor may affect significantly the safety and efficacy profiles of such a dual inhibitor in the treatment of cyclooxygenase-2 mediated disorders, compared to a cyclooxygenase-2 inhibitor without carbonic anhydrase inhibitory activity. | 2010-03-18 |
20100069484 | SIGMA(s)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION - The present invention involves new and original sigma receptors ligands : (Mono- or di-alkylaminoalkyl)-γ-butyrolactones, their analogues aminotetrahydrofuranes, the (1-adamantyl)phenyl(s) alkylamines, the N,N Dialkyl α-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or -alkyl phenylamines, their enantiomers or diastereoisomers and their pharmaceutically acceptable salts, with pro-apoptotic and/or anti-apoptotic properties over cellular bio-chemical mechanisms, with anti-cancer, anti-metastatic, anti-(chronic) inflammatory, neuro-protective, anticonvulsive, antidepressive and nooanaleptic or sedative action. | 2010-03-18 |
20100069485 | Method for maintaining freshness of fruits and vegetables - A process and a composition to extend the freshness of fruits and vegetables are disclosed. The method comprises treating fresh fruit or vegetable structures with a solution comprising organic acids including N-acetyl cysteine. | 2010-03-18 |
20100069486 | ANTI-TUMOR COMPOSITION - The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided. | 2010-03-18 |
20100069487 | METHOD FOR THE TREATMENT OF PSORIASIS - A method for the therapeutic treatment of psoriasis by the administration of an anti-psoriasis effective amount of Doxivir (CTC-96) is discloses. | 2010-03-18 |
20100069488 | Fire retardant composition - A composition can embrace a fire retardant can be combined with a fluoropolymer, which can be a coating, for example, a paint, especially a latex paint, or which can be an organic solvent based coating, for example, a paint. The fire retardant can be an ammonium phosphate containing fire retardant, which can be combined with a fluoropolymer, a penetrating barrier, borate-containing formulation having resistance to water damage with protective properties coming from materials used in food packaging and cosmetics, and/or a medium-to-long chain polar carboxyl substance to make a composition. Also, a composition can embrace a fire retardant formulation having a cross-linked component, which composition may be a coating, for example, a paint or stain, especially a latex paint. The cross-linked component may be a base of the paint or stain, say, a vinyl acetate base of the fire retardant latex paint. At least one other active agent, for example, a mold inhibitor and/or an insecticide, may be included. The composition can be used by contacting it with a substrate, which beneficially is otherwise flammable. The composition or its residue may be found in combination with the substrate. | 2010-03-18 |
20100069489 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX - The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same. | 2010-03-18 |
20100069490 | COMPOSITION FOR A PHARMACEUTICAL TREATMENT BASED ON TRIETHYL CITRATE AND ADAPALENE - The invention proposes a composition for pharmaceutical use containing as active principles triethyl citrate and adapalene in quantities efficacious for use in the treatment of cutaneous pathologies of inflammatory origin, caused by bacterial infections or altered lipid metabolism, both in the treatment of chronologic and photo induced cutaneous ageing, | 2010-03-18 |
20100069491 | LIPID-AMINO ACID CONJUGATES AND METHODS OF USE - N-fatty acid-amino acid conjugates and J | 2010-03-18 |
20100069492 | PRODUCTION OF ULTRAPURE EPA AND POLAR LIPIDS FROM LARGELY HETEROTROPHIC CULTURE - Eicosapentaenoic acid (EPA) compositions and EPA-rich polar lipids for prophylactic or therapeutic applications are described. Production from certain cultured micro-organisms (like | 2010-03-18 |
20100069493 | AQUEOUS PHARMACEUTICAL FORMULATION OF 4-[((4-CARBOXYBUTYL)-AMINO)METHYL]BENZOIC ACID - The present invention relates to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid or a salt thereof. The present invention relates in particular to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol). | 2010-03-18 |
20100069494 | LOWERING OF PROTEINS ASSOCIATED WITH ALZHEIMER'S DISEASE BY INTERRUPTING GENE TRANSCRIPTION WITH A SMALL MOLECULE - A method of treating Alzheimer's disease in a patient. The method includes administrating tolfenamic acid to the patient to modulate precursors of pothgene intermediates. The treatment also lowers SP1, APP and Aβ1 levels. | 2010-03-18 |
20100069495 | Topical application of adapalene for the long-term treatment of acne vulgaris - Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months. | 2010-03-18 |
20100069496 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS - The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia. | 2010-03-18 |
20100069497 | COMPOSITIONS COMPRISING JASMONIC ACID DERIVATIVES AND USE OF THESE DERIVATIVES - Cosmetic or pharmaceutical compositions comprising compounds of formula (I) and the corresponding salts thereof: | 2010-03-18 |
20100069498 | USE OF ALPHA-KETOGLUTARIC ACID FOR THE TREATMENT OF HIGH PLASMA GLUCOSE CONDITION - A method for improving adsorption of amino acids in a vertebrate, including mammal and bird, is included. The method comprises administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, AKG, AKG derivates or metabolites, AKG analogues or mixtures thereof. Also contemplated is a method for decreasing adsorption of glucose in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, AKG, AKG derivates or metabolites, AKG analogues or mixtures thereof, for decreasing glucose adsorption as well as compositions for use in treatment. | 2010-03-18 |
20100069499 | AMIDE COMPOUND AND USE THEREOF - Disclosed is an amide compound represented by the formula (1) below, which has excellent plant disease controlling activity. | 2010-03-18 |
20100069500 | AMIDE DENDRIMER COMPOSITIONS - Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester. | 2010-03-18 |
20100069501 | Pharmaceutical Composition Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and Paracetamol - A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) Paracetamol or a derivative thereof; a pharmaceutical composition and/or dosage form comprising such a combination as well as a method of treating one or more of pain and ostheoarthritis in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to said mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 2010-03-18 |
20100069502 | Assay - The invention relates to a method for identifying a candidate agent for use in a medicament for diabetes or obesity said method comprising (i) providing a candidate inhibitor of PPM phosphatase, (ii) providing a first and a second sample comprising PPM phosphatase, (iii) contacting said candidate inhibitor with said first sample comprising PPM phosphatase, and (iv) assaying said first and second samples for PPM phosphatase activity, wherein said PPM phosphatase is selected from the group consisting of PPM1E, PPM1F, PPM1J, PPM1K, PPM1L and PPM1M, wherein if the PPM phosphatase activity is lower in said first sample than in said second sample then said candidate inhibitor is identified as a candidate agent for use in a medicament for diabetes or obesity, preferably type II diabetes. The invention also relates to the use of metformin and phenformin as inhibitors of PPM phosphatases. | 2010-03-18 |
20100069503 | INHIBITION OF MITOGEN-ACTIVATED PROTEIN KINASES IN CARDIOVASCULAR DISEASE - The present invention relates to methods for inhibiting subacute thrombosis and/or intimal hyperplasia following an interventional vascular procedure by contacting a blood vessel or a synthetic material with a mitogen-activated protein kinase (MAPK) pathway inhibitor. The present invention further relates to vascular devices comprising a MAPK pathway inhibitor. | 2010-03-18 |
20100069504 | AMINOBENZOCYCLOHEPTENE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USES THEREOF IN THERAPY - A compound of the general formula (I) as an active principle for treating cancer, specifically tumors, in particular diseases involving inhibition of metalloproteases, such as Aminopeptidase-N. Pharmaceutical compositions comprising the compound of general formula (I). Methods of treatment using the compound of general formula (I). | 2010-03-18 |
20100069505 | ALCOHOLIC PUMP FOAM - An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to ≦99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam stabilizer, e) optionally, at least one member selected from the group consisting of cosmetic auxiliaries, adjuvants, active ingredients, and mixtures thereof, and f) optionally water. The surface tension of component b) lies in the range of ±15 dyn/cm of the surface tension of component a) or corresponds to the surface tension of component a), and the sum of components a) to f) is 100 wt % relative to the total quantity of the foam composition. | 2010-03-18 |
20100069506 | COMPOSITION FOR PEST CONTROL - Compositions suitable for the control of pest amphibian species are described. More particularly, compositions for killing amphibians are described that comprise:
| 2010-03-18 |
20100069507 | Porous Carbon Materials and Production Process Thereof, and Adsorbents, Masks, Adsorbing Sheets and Carriers - By a process for producing a porous carbon material from a plant-derived material as a raw material, said process including carbonizing the plant-derived material at 800° C. to 1,400° C. and then applying a treatment with an acid or alkali, a porous carbon material having a value of specific surface area of at least 10 m | 2010-03-18 |
20100069508 | Organic Compounds - Described are 2,2,3-trimethylcyclopentane derivatives of formula 1 | 2010-03-18 |
20100069509 | NONIONIC EMULSIFIERS FOR EMULSION CONCENTRATES FOR SPONTANEOUS EMULSIFICATION - The present invention relates to a nonionic emulsifier for spontaneous emulsification, containing a chemical compound having the general structure tallow alcohol -n PO-m EO, the average number of hydrocarbon atoms of the tallow alcohol amounting to between 16 and 18, and the iodine count being lower than or equal to 1 g of iodine/100 g of the chemical compound. The average degree of propoxylation is between 1 and 4, and the average degree of ethoxylation is between 2 and 6. | 2010-03-18 |
20100069510 | PROCESS FOR THE MANUFACTURE OF A POWDER CONTAINING CAROTENOIDS - The present invention relates to a process for the manufacture of an emulsion or dispersion containing one or more carotenoids, in a preferred embodiment it relates to the manufacture of a powder containing one or more carotenoids, furthermore to the powder obtainable by said process and a food composition, especially a beverage, containing said powder. | 2010-03-18 |